New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 24, 2012
10:01 EDTBUD, APD, CLS, NTAP, UTHR, NSC, VMED, DCI, DD, CTCM, ATML, ILMNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AB InBev (BUD) downgraded to Sell from Neutral at Goldman... Atmel (ATML) downgraded to Neutral from Buy at Nomura... CTC Media (CTCM) downgraded to Hold from Buy at Deutsche Bank... Donaldson (DCI) downgraded to Hold from Buy at Jefferies... DuPont (DD) downgraded to Neutral from Overweight at JPMorgan... Norfolk Southern (NSC) downgraded to Neutral from Buy at Citigroup... United Therapeutics (UTHR) downgraded to Underweight from Neutral at JPMorgan... Virgin Media (VMED) downgraded to Neutral from Buy at Citigroup... Air Products (APD) downgraded to Hold from Buy at KeyBanc... Celestica (CLS) downgraded to Hold from Speculative Buy at Canaccord... NetApp (NTAP) downgraded to Market Perform from Outperform at BMO Capital... United Therapeutics (UTHR) downgraded to Market Perform from Outperform at BMO Capital... Illumina (ILMN) downgraded to Underperform from Outperform at CLSA.
Check below for free stories on BUD;ATML;CTCM;DD;DCI;VMED;NSC;UTHR;NTAP;CLS;APD;ILMN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 29, 2014
13:05 EDTUTHRUnited Therapeutics price target raised to $141 from $133 at Wedbush
Subscribe for More Information
12:53 EDTUTHRCourt ruling in Remodulin patent case favors United Therapeutics
Subscribe for More Information
12:49 EDTUTHRStocks with increasing volume options volume
Stocks with increasing volume options volume: OXY HD RSH UTHR IRF TTWO CONN
12:18 EDTUTHROn The Fly: Midday Wrap
Subscribe for More Information
11:07 EDTUTHRHigh option volume stocks
Subscribe for More Information
10:51 EDTUTHRUnited Therapeutics jumps after court rules generic will infringe
United Therapeutics (UTHR) alleged patent infringement against Sandoz, a unit of Novartis (NVS), related to the latter's filing for approval of a generic version of United Therapeutics' remodulin drug. A New Jersey court ruled today that Sandoz's proposed ANDA product will infringe the claims of UTC's '117 patent, according to a court filing. Following the court ruling, shares of United Therapeutics are up 15% to $105.39 in morning trading.
August 28, 2014
08:15 EDTDCIDonaldson price target raised to $47 from $42 at Jefferies
Jefferies raised its price target on Donaldson to $47 after the company's Q4 beat, but the firm maintains its Hold rating on the shares as it believes the stock will be range bound as its FY15 growth is expected to come mainly in the second half of the fiscal year.
06:24 EDTDDDuPont to pay $1.28 to resolve toxic gas leak allegations
Subscribe for More Information
August 27, 2014
06:06 EDTDCIDonaldson sees FY15 EPS $1.81-$2.01, consensus $1.93
Subscribe for More Information
06:05 EDTDCIDonaldson reports Q4 EPS 50c, consensus 47c
Subscribe for More Information
August 26, 2014
15:36 EDTDCINotable companies reporting before tomorrow's open
Subscribe for More Information
15:04 EDTNTAPNetApp extends alliance with VMware on cloud computing
Subscribe for More Information
09:25 EDTDDFarm Progress Companies to hold a show
Subscribe for More Information
August 25, 2014
14:21 EDTAPDAir Products licenses ICEFLY technology to Advanced Research Systems
Air Products announced it has licensed its proprietary cryogenic machining technology to Advanced Research Systems, a manufacturer of industrial and research cryogenic equipment. The technology license agreement gives ARS extensive rights to Air Products' patented ICEFLY Cryogenic Machining Technology. Included in the agreement is the transfer of ICEFLY cryogen delivery equipment design information and cryogenic machining know-how developed by Air Products.
August 21, 2014
12:12 EDTDDDuPont files patent infringement lawsuit against SunEdison
Subscribe for More Information
08:14 EDTATMLAtmel, Fairchild potential takeover candidates, says FBR Capital
Subscribe for More Information
05:42 EDTILMNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
10:04 EDTILMNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:18 EDTILMNIllumina upgraded to Outperform from Neutral at Wedbush
Subscribe for More Information
August 19, 2014
11:32 EDTILMNLabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use